What Causes Joint Pain? The Mechanisms Behind OA, Inflammation, and Cartilage Breakdown
What causes joint pain depends on which structure is failing: osteoarthritis damages cartilage through mechanical wear and inflammatory degradation, while rheumatoid arthritis attacks the synovial lining through an autoimmune process, and gout triggers acute crystal-induced inflammation in the joint space. Each cause involves distinct biology — and distinguishing them determines whether the treatment is mechanical (load modification, targeted exercise), pharmacological (NSAIDs, DMARDs), nutritional, or surgical. This guide maps the full landscape of joint pain causes using primary research rather than supplement-category marketing.
Joint pain affects an estimated 528 million people globally with osteoarthritis alone, according to the 2019 Global Burden of Disease study. When you add inflammatory arthritis, post-traumatic joint disease, and the broader category of periarticular soft tissue disorders, joint pain becomes one of the most prevalent reasons adults seek medical care and modify their physical activity. As a Registered Dietitian Nutritionist, I find the biology of joint deterioration genuinely important context for any conversation about joint health interventions — nutritional or otherwise.
TL;DR
- The most common cause of joint pain is osteoarthritis — progressive cartilage breakdown driven by mechanical stress, aging, and inflammatory cytokines.
- Inflammatory arthritis (rheumatoid, psoriatic, gout) is less common but more systemically destructive; it’s diagnosed by blood markers and synovial fluid analysis, not imaging alone.
- Cartilage has no blood supply and cannot self-repair in any meaningful way — which is why prevention and slowing progression are the realistic clinical goals.
- Inflammation drives most joint pain regardless of the underlying cause: cytokines (IL-1β, IL-6, TNF-α) and matrix metalloproteinases (MMPs) are the final common pathway in cartilage destruction.
- Nutritional and supplement interventions that target the 5-LOX and COX inflammatory cascades, cartilage matrix turnover, and synovial fluid quality have the strongest biological rationale for joint support.
The Anatomy of a Joint: What Can Go Wrong
Understanding what causes joint pain starts with what a healthy joint actually is. A synovial joint — the type at the knee, hip, shoulder, hands, and spine — consists of several interacting structures, each of which can become a pain source.
Articular cartilage is the smooth, white tissue that lines the ends of bones at the joint. It has no nerves and no blood supply — which is why early cartilage damage produces no pain, and also why it cannot heal once damaged. Cartilage is composed primarily of type II collagen fibers embedded in a proteoglycan matrix (mainly aggrecan), with chondrocytes (cartilage cells) scattered throughout. It functions as a frictionless bearing surface and a shock absorber.
Synovial membrane (synovium) lines the joint capsule and secretes synovial fluid — a viscous lubricant rich in hyaluronic acid, lubricin, and growth factors that nourishes the avascular cartilage and reduces friction during movement. In inflammatory arthritis, the synovium becomes the primary disease site — it hypertrophies (pannus formation in RA), becomes highly vascularized, and secretes destructive enzymes and inflammatory cytokines that spill over into the joint space.
Subchondral bone — the bone immediately beneath the cartilage — also participates in OA progression. As cartilage thins, subchondral bone undergoes remodeling: osteophytes (bone spurs) form at joint margins, and the bone plate becomes denser and less shock-absorbing. Subchondral bone contains nerve endings, which is why advanced OA produces bone-on-bone pain.
Periarticular tissues — muscles, tendons, ligaments, and the bursae (fluid-filled sacs that reduce friction) — are frequent pain sources independent of cartilage damage. Bursitis and tendinitis are often misattributed to arthritis.
Cause 1: Osteoarthritis — Mechanical Failure With an Inflammatory Driver
Osteoarthritis was historically described as “wear and tear” disease — implying a passive, mechanical process of cartilage erosion through use. This framing is no longer accurate. The current model recognizes OA as an active biological process in which mechanical stress initiates cellular signaling cascades that produce destructive inflammation.
The core mechanism: When cartilage is stressed — by excess load, altered joint biomechanics, or cumulative microtrauma — chondrocytes respond by producing matrix metalloproteinases (MMPs), particularly MMP-1, MMP-3, and MMP-13. These collagenolytic enzymes break down type II collagen and aggrecan at rates that outpace repair. Simultaneously, chondrocytes, synoviocytes, and infiltrating macrophages produce pro-inflammatory cytokines: interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) are the primary drivers, inducing further MMP production, inhibiting new collagen synthesis, and triggering chondrocyte apoptosis (cell death).
Why the inflammatory component matters clinically: The synovial fluid of OA joints, once thought uninflamed, contains elevated concentrations of IL-1β, IL-6, and TNF-α — not as elevated as in RA, but measurably higher than healthy joints. This synovitis is now recognized as contributing substantially to OA pain and progression. Hunter et al. (Nature Reviews Rheumatology, 2015) quantified synovial inflammation in imaging studies of knee OA and found that synovitis severity independently predicted both pain intensity and radiographic OA progression.
What accelerates OA:
- Excess body weight: Each kilogram of mass generates approximately 4 kilograms of force across the knee during walking. A 2020 meta-analysis in Arthritis Care & Research found that obesity increases OA risk by 2.7-fold, independent of mechanical loading — visceral adipose tissue itself secretes leptin, adiponectin, and pro-inflammatory cytokines (adipokines) that exacerbate synovial inflammation.
- Joint injury history: ACL tears, meniscus damage, and major ligament injuries increase OA risk dramatically. Multiple cohort studies document OA rates of 50–80% within 15 years of ACL injury — even with surgical reconstruction — explaining why early-onset knee OA is common in former athletes.
- Repetitive occupational loading: Kneeling, squatting, and heavy lifting occupations show significantly elevated knee and hip OA incidence in epidemiological data.
- Age: Cartilage repair capacity declines with age partly because chondrocyte senescence (accumulation of metabolically dysfunctional cells) increases. The proportion of senescent chondrocytes in OA cartilage is markedly elevated vs healthy age-matched tissue.
For practical guidance on the ingredients that address the MMP and cytokine pathways pharmacologically, our best joint supplement ingredients guide covers the clinical evidence in depth.
Cause 2: Rheumatoid Arthritis — Autoimmune Synovial Attack
Rheumatoid arthritis (RA) is a systemic autoimmune disease in which the immune system produces antibodies — primarily anti-citrullinated protein antibodies (anti-CCP) and rheumatoid factor (RF) — that target proteins within joint synovium. The resulting immune complex deposition triggers aggressive synovial inflammation and hypertrophy (pannus formation), with inflammatory cells (macrophages, T cells, B cells) directly invading the cartilage-bone junction.
Unlike OA, which begins in the cartilage, RA begins in the synovium and destroys cartilage from the outside in. The synovial pannus tissue erodes both cartilage and bone, producing the characteristic periarticular bone erosions visible on X-ray in established RA. Without disease-modifying treatment (DMARDs, biologics), RA causes progressive joint destruction and disability.
Key distinguishing features from OA:
- Symmetric joint involvement (same joints affected on both sides)
- Morning stiffness lasting more than 1 hour (OA stiffness typically resolves within 30 minutes)
- Positive anti-CCP or RF blood tests in seropositive RA
- Systemic features: fatigue, low-grade fever, weight loss
- Extraarticular manifestations: rheumatoid nodules, interstitial lung disease, cardiovascular risk elevation
RA prevalence is approximately 0.5–1% of the global adult population (Smolen et al., Nature Reviews Disease Primers, 2018), substantially lower than OA. However, RA produces more aggressive joint destruction when untreated.
Cause 3: Gout and Crystal Arthropathies — Acute Inflammatory Flares
Gout is caused by hyperuricemia — elevated serum uric acid — which exceeds the solubility threshold and causes monosodium urate (MSU) crystals to deposit in joint spaces, tendons, and periarticular tissue. Macrophages phagocytose these crystals and respond by releasing massive amounts of IL-1β and neutrophil-activating chemokines, producing the characteristic acute gout flare: sudden, severe, hot, swollen joint pain — classically in the first metatarsophalangeal joint (big toe) — that reaches maximum intensity within 12–24 hours.
Dalbeth et al. (Nature Reviews Disease Primers, 2019) provides an excellent review of gout pathophysiology. Key drivers of hyperuricemia:
- Dietary purines: Red meat, organ meat, shellfish, and high-fructose corn syrup are major urate precursors
- Alcohol: Especially beer and spirits, which both raise urate production and impair renal urate excretion
- Renal function decline: 70% of uric acid is excreted renally; kidney disease accumulates urate
- Diuretic medications: Thiazide and loop diuretics reduce urate excretion
- Genetics: Variants in ABCG2 and SLC2A9 genes significantly affect urate transport
Pseudogout (calcium pyrophosphate deposition disease, CPPD) shares a similar mechanism but involves calcium pyrophosphate crystals depositing in cartilage (chondrocalcinosis). It typically affects larger joints — knee, wrist, shoulder — rather than the first MTP joint of gout.
Cause 4: Post-Traumatic Joint Damage
Post-traumatic osteoarthritis (PTOA) is the third leading cause of OA globally and is particularly prevalent in people under 50. It develops following ligament ruptures (particularly ACL), meniscal tears, osteochondral fractures, and major joint dislocations.
The mechanism overlaps significantly with primary OA: acute injury releases inflammatory mediators and matrix-degrading enzymes into the joint space. In the synovial fluid of ACL-injured knees, IL-1β, IL-6, MMP-1, and MMP-3 are measurably elevated within hours of injury — and can remain elevated for months. This acute inflammatory environment initiates a degenerative cascade that persists long after the ligament itself has healed.
A landmark prospective cohort study (Roos et al., Osteoarthritis Cartilage, 1995) found that 50% of women with ACL tears developed radiographic knee OA within 15 years, regardless of whether they underwent surgical reconstruction. The injury itself — not just the mechanical instability — sets the degenerative cascade in motion.
Cause 5: Periarticular Soft Tissue Conditions
Not all joint-area pain originates from the joint itself. Several periarticular conditions produce pain that mimics joint pathology:
Bursitis: Inflammation of the bursae — fluid-filled sacs near major joints that reduce friction between tendons and bone. Prepatellar bursitis (kneecap area), trochanteric bursitis (lateral hip), and subacromial bursitis (shoulder) are common and painful without involving articular cartilage.
Tendinitis and tendinopathy: Degenerative changes in the tendons surrounding a joint — patellar tendinitis, iliotibial band syndrome, and rotator cuff tendinopathy are frequent sources of periarticular knee and shoulder pain in active adults.
Referred pain from the spine: Lumbar facet joint OA and degenerative disc disease can refer pain into the hip, buttock, and knee. Cervical spine pathology refers into the shoulder and arm. Patients sometimes undergo knee or hip evaluation before the spinal origin is identified.
Fibromyalgia: A central sensitization syndrome producing widespread musculoskeletal pain and tenderness at periarticular points, without structural joint pathology. Often misclassified as polyarthritis.
The Final Common Pathway: Synovial Inflammation
Regardless of the underlying cause — mechanical, autoimmune, crystal-induced, or post-traumatic — the immediate cause of joint pain is synovial inflammation. The pain-sensing nerves in joint tissue are in the synovium, periosteum, and periarticular ligaments — not in the cartilage itself. Inflammatory mediators in the synovial fluid sensitize these nociceptors and lower their pain threshold.
The central cytokine network in joint inflammation:
| Cytokine | Source | Primary Effect on Joint |
|---|---|---|
| IL-1β | Macrophages, chondrocytes | Induces MMP production; inhibits collagen synthesis |
| TNF-α | Macrophages, synoviocytes | Drives synovitis; synergizes with IL-1β on MMP induction |
| IL-6 | Synoviocytes, macrophages | Promotes systemic inflammation; drives osteoclast activation |
| IL-17 | T cells (RA-predominant) | Amplifies synovial inflammation; promotes pannus invasion |
| PGE₂ | Cyclooxygenase-2 (COX-2) pathway | Directly sensitizes nociceptors; drives synovial vasodilation |
| LTB₄ | 5-Lipoxygenase (5-LOX) pathway | Promotes neutrophil infiltration; amplifies acute joint inflammation |
Why this table matters for interpreting supplement evidence: NSAIDs block the COX pathway (prostaglandin production). Boswellia serrata — particularly the AprèsFlex® form used in products like Joint Genesis — selectively inhibits 5-LOX, targeting a distinct and complementary pro-inflammatory cascade. Understanding which pathway a given intervention targets helps evaluate whether ingredients are mechanistically redundant or complementary.
How Cartilage Loss Becomes Pain: The Stage Progression
A useful framework for understanding when and why OA becomes painful:
Stage 0 (Normal): Cartilage is intact; no symptoms.
Stage 1 (Minimal): Superficial cartilage fibrillation (surface softening), mild synovitis detectable on MRI. Often asymptomatic or causing only occasional post-activity soreness.
Stage 2 (Mild): Partial-thickness cartilage loss; visible narrowing on X-ray. Pain after prolonged activity; morning stiffness resolving within 30 minutes. Most people first seek care at this stage.
Stage 3 (Moderate): Full-thickness cartilage loss over small areas; osteophyte formation; subchondral bone exposure. Regular pain at rest and during activities; functional limitation.
Stage 4 (Severe): Extensive full-thickness cartilage loss; severe joint-space narrowing or obliteration; bone-on-bone contact. Constant pain; significant mobility loss. Joint replacement becomes the dominant evidence-supported option.
The clinical implication: supplement and nutrition interventions are most biologically meaningful at Stages 1–3, where cartilage degradation can potentially be slowed and inflammation managed. At Stage 4, the structural substrate for these mechanisms is largely lost. This timing context is why the glucosamine sulfate three-year structural trial was designed to measure joint-space narrowing rate — the relevant endpoint at stages where preservation, not reversal, is the realistic goal.
Risk Factors That Accelerate Joint Deterioration
Understanding the modifiable risk factors provides actionable targets for joint pain prevention and management:
Body weight: The relationship between obesity and OA is dose-dependent. Jiang et al. (Arthritis & Rheumatology, 2012) found that every 5 kg/m² increase in BMI raised OA risk by 35%. The mechanism is partly mechanical (load amplification), partly metabolic (adipokine-driven inflammation).
Physical inactivity: Counterintuitively, physical inactivity accelerates cartilage degeneration. Cartilage is avascular and receives nutrients from synovial fluid via diffusion — a process that depends on the pressure changes created by joint loading during movement. Regular low-impact loading (walking, cycling, swimming) maintains cartilage nutrition. Roos and Dahlberg (Arthritis & Rheumatism, 2005) demonstrated that exercise maintained cartilage proteoglycan content vs. inactivity controls in OA patients.
Muscle weakness: Periarticular muscle strength — particularly the quadriceps for knee OA — acts as a mechanical buffer, distributing joint load and protecting cartilage. Quadriceps weakness is both a consequence of OA pain and an independent predictor of OA progression in longitudinal studies.
Smoking: Despite anti-inflammatory properties of nicotine in some models, smoking consistently associates with worse OA severity and worse outcomes in inflammatory arthritis. The mechanism likely involves oxidative stress impairment of cartilage repair pathways.
Hormonal status: Estrogen has a chondroprotective effect — OA incidence accelerates in women after menopause, and the knee is the most affected joint. This sex difference in OA incidence (women > men after age 50) is partially explained by estrogen loss.
Diet and systemic inflammation: High ultra-processed food consumption, elevated omega-6 to omega-3 fatty acid ratios, and low dietary fiber intake are associated with higher circulating inflammatory markers. A 2020 meta-analysis in Nutrients found Mediterranean diet adherence was significantly associated with lower OA pain and better physical function.
Nutrition, Supplements, and the Joint Pain Cascade
Nutritional approaches to joint pain work by modulating the inflammatory signaling cascades described above — not by structurally repairing cartilage. This distinction is important for setting realistic expectations.
Anti-inflammatory dietary pattern: Prioritizing omega-3-rich foods (fatty fish, flaxseed, walnuts), colorful vegetables (polyphenols with COX and NF-κB modulating properties), and minimizing refined carbohydrates and trans fats addresses the systemic inflammatory background that amplifies joint pain.
Omega-3 fatty acids: EPA and DHA are precursors to pro-resolving mediators (resolvins, protectins) that actively terminate inflammatory responses. The 2006 Cochrane review on omega-3s in RA documented significant reductions in joint pain at 3g/day EPA+DHA.
Glucosamine sulfate: Supplies building blocks for glycosaminoglycan synthesis and may stimulate chondrocyte proteoglycan production. The Reginster et al. (The Lancet, 2001) three-year trial showed measurable slowing of joint-space narrowing — the most compelling structural evidence for any oral supplement. Our glucosamine vs chondroitin comparison breaks down the GAIT trial subgroup data and the critical form distinction (sulfate vs HCl) in clinical detail.
Chondroitin sulfate: Inhibits MMPs and aggrecanases — directly blocking the enzymes responsible for cartilage matrix degradation. The MOVES trial (Seminars in Arthritis and Rheumatism, 2016) found chondroitin at 800 mg/day performed comparably to celecoxib 200 mg on pain outcomes.
Collagen: Both hydrolyzed collagen peptides (10–15g/day as amino acid substrate) and UC-II undenatured type II collagen (40 mg/day via oral tolerization) have distinct roles in supporting joint tissue. Our collagen and joint health guide covers the mechanism differences and clinical trial data.
Boswellia serrata: Selectively inhibits 5-LOX — the leukotriene pathway operating in parallel with the COX cascade targeted by NSAIDs. Joint Genesis uses AprèsFlex® Boswellia alongside Mobilee® hyaluronic acid — addressing synovial fluid quality and inflammatory modulation in a single formula. Ageless Knees takes a different protocol-based approach that integrates targeted movement rehabilitation with supplemental support. Our full reviews of JointVive and MoveWell Daily cover two additional formulation strategies for supporting joint health over time.
For a comprehensive ranking of every major joint supplement ingredient by evidence quality, with therapeutic doses and trial citations, see our best joint supplement ingredients guide.
When to See a Doctor
Most joint pain that develops gradually and is associated with activity or aging can be appropriately addressed with lifestyle modification, physical therapy, and evidence-supported nutrition strategies. However, several presentations require prompt medical evaluation:
See a physician urgently if:
- Sudden, severe single-joint pain (especially knee, ankle, big toe) — could be gout, pseudogout, or septic arthritis
- Fever accompanying joint pain — septic arthritis is a medical emergency
- Red, hot, swollen joint with no prior history — infection or crystal arthritis
- Trauma resulting in joint deformity, inability to bear weight, or locking
See a physician for scheduled evaluation if:
- Joint pain lasting more than 6 weeks without improvement
- Morning stiffness lasting more than 45 minutes
- Symmetric joint involvement affecting multiple joints
- Joint pain accompanied by fatigue, skin changes, or eye inflammation
- Pain that does not improve with rest or over-the-counter analgesics
Frequently Asked Questions
What is the most common cause of joint pain?
Osteoarthritis is the most common cause, affecting 528 million people globally per the GBD 2019 study. It results from progressive cartilage degradation driven by mechanical stress, MMP overproduction, and inflammatory cytokine signaling — not simply from aging or use alone.
What causes sudden joint pain without an injury?
Sudden non-traumatic joint pain is most often gout (uric acid crystal deposition triggering acute IL-1β-driven inflammation), pseudogout (calcium pyrophosphate crystals), infectious arthritis (septic arthritis — a medical emergency), or an acute flare of rheumatoid or psoriatic arthritis. Sudden severe single-joint pain warrants same-day physician evaluation to exclude infection.
What causes joint pain in multiple joints at once?
Polyarthritis affecting five or more joints simultaneously suggests a systemic inflammatory etiology: rheumatoid arthritis (symmetric, anti-CCP positive), psoriatic arthritis, lupus-associated arthritis, or viral arthritis (post-parvovirus B19, post-hepatitis B). Morning stiffness exceeding one hour strongly indicates inflammatory autoimmune disease over mechanical OA.
Does diet cause joint pain?
Diet does not cause structural joint disease, but it meaningfully modulates inflammatory signaling and pain intensity. Mediterranean dietary patterns are associated with lower OA pain scores. Gout is the clearest exception — dietary purines and fructose directly raise serum urate, triggering crystal deposition and acute flares.
What causes joint pain in young people?
In adults under 40, the most common causes are post-traumatic damage (ACL tears, meniscal injuries), overuse injuries from athletic activity, early inflammatory arthritis, and hypermobility spectrum disorders. Early-onset OA following ACL injury is increasingly well-documented, with 50–80% OA rates in long-term cohort studies regardless of surgical repair.
Can damaged joint cartilage be repaired?
Articular cartilage lacks blood vessels and self-repair capacity. Established cartilage loss does not regenerate under any current supplement, drug, or lifestyle intervention. The most evidence-supported goal is slowing the rate of further loss — which is what glucosamine sulfate’s three-year structural trial (Reginster, The Lancet, 2001) demonstrated as a meaningful outcome endpoint.
What supplements have evidence for joint pain?
Glucosamine sulfate (1,500 mg/day), chondroitin sulfate (800–1,200 mg/day), Boswellia serrata as AprèsFlex® (100 mg/day), and MSM (3g/day) have the strongest RCT evidence for symptomatic relief in OA. Mobilee® hyaluronic acid (80 mg/day) and UC-II undenatured collagen (40 mg/day) have meaningful secondary evidence. No supplement reverses existing joint damage.
What is the difference between arthritis and joint pain?
Joint pain is a symptom. Arthritis is a diagnosis — a category encompassing over 100 conditions, most commonly OA and RA. Not all joint-area pain is arthritis; bursitis, tendinitis, referred spinal pain, and fibromyalgia all produce joint-area pain without articular pathology. Diagnosis requires clinical evaluation, often including imaging and blood work.
What makes joint pain worse?
Established amplifying factors: excess body weight (4x mechanical force multiplication at the knee), physical inactivity (impairs cartilage nutrition), muscle weakness (particularly quadriceps), high ultra-processed food intake, smoking, metabolic syndrome, and sleep deprivation (raises morning inflammatory markers).
The Bottom Line
What causes joint pain is not a single answer — it’s a spectrum of conditions with distinct biological mechanisms that happen to share a common endpoint: inflammatory sensitization of the nociceptors surrounding joint tissue. Osteoarthritis, the most prevalent, begins as mechanical stress-induced MMP overproduction and evolves into an active inflammatory-degenerative cycle. Rheumatoid arthritis starts in the synovium as an autoimmune attack. Gout is crystal-induced acute inflammation. Post-traumatic OA is injury-initiated degenerative cascade.
The common thread in nearly all joint pain — and the reason anti-inflammatory strategies are clinically meaningful across different etiologies — is the cytokine network: IL-1β, TNF-α, IL-6, prostaglandins, and leukotrienes drive synovial inflammation and nociceptor sensitization regardless of what initiated the cascade.
For people in the OA spectrum specifically, the evidence supports that slowing cartilage degradation, reducing synovial inflammation, and maintaining periarticular muscle strength are the most impactful modifiable variables. Nutritional and supplement interventions that address the MMP cascade (glucosamine, chondroitin), the 5-LOX pathway (Boswellia), and synovial fluid quality (hyaluronic acid) are biologically coherent complements to physical activity and dietary optimization — not replacements for medical evaluation and treatment.
For a deep-dive into which specific ingredients address which mechanisms and what the clinical trial doses look like, our best joint supplement ingredients guide is the companion resource to this article. For the key form differences between the two most studied compounds, our glucosamine vs chondroitin comparison covers the GAIT trial, the Cochrane evidence, and what to look for on a label.
Learn more about our research methodology and reviewer credentials on our About page. Disclosure practices are detailed at our disclosure page.
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement program or making changes to your treatment plan, especially if you have a diagnosed medical condition or take prescription medications.